GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (NAS:NKTR) » Definitions » Cyclically Adjusted PS Ratio

NKTR (Nektar Therapeutics) Cyclically Adjusted PS Ratio : 0.93 (As of Jul. 03, 2025)


View and export this data going back to 1994. Start your Free Trial

What is Nektar Therapeutics Cyclically Adjusted PS Ratio?

As of today (2025-07-03), Nektar Therapeutics's current share price is $24.76. Nektar Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was $26.67. Nektar Therapeutics's Cyclically Adjusted PS Ratio for today is 0.93.

The historical rank and industry rank for Nektar Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:

NKTR' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.23   Med: 8.97   Max: 81.75
Current: 0.96

During the past years, Nektar Therapeutics's highest Cyclically Adjusted PS Ratio was 81.75. The lowest was 0.23. And the median was 8.97.

NKTR's Cyclically Adjusted PS Ratio is ranked better than
84.46% of 489 companies
in the Biotechnology industry
Industry Median: 5.64 vs NKTR: 0.96

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Nektar Therapeutics's adjusted revenue per share data for the three months ended in Mar. 2025 was $0.744. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $26.67 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Nektar Therapeutics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Nektar Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nektar Therapeutics Cyclically Adjusted PS Ratio Chart

Nektar Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.34 7.01 1.12 0.29 0.50

Nektar Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 0.63 0.70 0.50 0.38

Competitive Comparison of Nektar Therapeutics's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Nektar Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nektar Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Nektar Therapeutics's Cyclically Adjusted PS Ratio falls into.


;
;

Nektar Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Nektar Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=24.76/26.67
=0.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nektar Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Nektar Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.744/134.9266*134.9266
=0.744

Current CPI (Mar. 2025) = 134.9266.

Nektar Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 2.582 100.684 3.460
201509 6.780 100.392 9.112
201512 4.401 99.792 5.950
201603 6.504 100.470 8.735
201606 3.605 101.688 4.783
201609 3.975 101.861 5.265
201612 3.767 101.863 4.990
201703 2.414 102.862 3.166
201706 3.340 103.349 4.361
201709 14.104 104.136 18.274
201712 9.043 104.011 11.731
201803 3.544 105.290 4.542
201806 89.502 106.317 113.587
201809 2.411 106.507 3.054
201812 3.289 105.998 4.187
201903 2.435 107.251 3.063
201906 2.004 108.070 2.502
201909 2.499 108.329 3.113
201912 2.884 108.420 3.589
202003 4.281 108.902 5.304
202006 4.109 108.767 5.097
202009 2.516 109.815 3.091
202012 1.958 109.897 2.404
202103 1.956 111.754 2.362
202106 2.326 114.631 2.738
202109 2.030 115.734 2.367
202112 2.028 117.630 2.326
202203 2.003 121.301 2.228
202206 1.733 125.017 1.870
202209 1.889 125.227 2.035
202212 1.755 125.222 1.891
202303 1.715 127.348 1.817
202306 1.621 128.729 1.699
202309 1.902 129.860 1.976
202312 1.875 129.419 1.955
202403 1.667 131.776 1.707
202406 1.687 132.554 1.717
202409 1.729 133.029 1.754
202412 2.086 133.157 2.114
202503 0.744 134.927 0.744

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Nektar Therapeutics  (NAS:NKTR) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Nektar Therapeutics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Nektar Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nektar Therapeutics Business Description

Traded in Other Exchanges
Address
455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
Executives
Howard W Robin director, officer: President & CEO
Jonathan Zalevsky officer: Chief R&D Officer 455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158
Mark Andrew Wilson officer: SVP & General Counsel 1613 RAY DRIVE, BURLINGAME CA 94010
Robert Chess director, officer: Executive Chairman
Myriam Curet director 1020 KIFER ROAD, SUNNYVALE CA 94086
Jeffrey Robert Ajer director C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Sandra A. Gardiner officer: Chief Financial Officer CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Jillian B. Thomsen officer: VP & Chief Accounting Officer C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Karin Eastham director C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR, 10901 N. TORREY PINES ROAD, LA JOLLA CA 92037
Gil M Labrucherie officer: SVP, COO & CFO 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
John Northcott officer: SVP & Chief Commercial Officer 455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158
Diana Brainard director C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
R Scott Greer director 6207 E. INDIAN BEND RD, PARADISE VALLEY AZ 85253
Lutz Lingnau director 15 INDIAN HOLLOW ROAD, MENDHAM NJ 07945
Stephen K Doberstein officer: Chief Scientific Officer 129 ELSIE STREET, SAN FRANCISCO CA 94110